Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

decernotinib

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
OBJECTIVE To assess the efficacy and safety of decernotinib (VX-509), an oral selective inhibitor of JAK-3, in patients with… Expand
Is this relevant?
2016
2016
OBJECTIVE To assess early effects on joint structures of VX-509 in combination with stable disease-modifying antirheumatic drug… Expand
Is this relevant?
2016
2016
(R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide (VX-509, decernotinib… Expand
Is this relevant?
2016
2016
Since the beginning of this millennium, rheumatologists have become applied cytokine biologists, taking advantage of the plethora… Expand
  • figure 1
Is this relevant?
2015
2015
OBJECTIVE To assess the efficacy and safety of oral decernotinib (VX-509; Vertex Pharmaceuticals) monotherapy in a 12-week… Expand
Is this relevant?
2015
2015
Cytokines, growth factors, and other chemical messengers rely on a class of intracellular nonreceptor tyrosine kinases known as… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2015
2015
Background VX-509 is an oral selective Janus Kinase 3 inhibitor that has been studied in patients with rheumatoid arthritis (RA… Expand
Is this relevant?
2014
2014
Background VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). This was a… Expand
Is this relevant?